Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma

Basit Öğe Kaydı
dc.authorid0000-0002-4303-9488en_US
dc.authorid0000-0002-5603-1178en_US
dc.authorid0000-0001-7588-6000en_US
dc.authorid0000-0002-2690-8581en_US
dc.authorid0000-0002-1430-0341en_US
dc.contributor.authorŞumnu, Şeyma
dc.contributor.authorMehtap, Özgür
dc.contributor.authorMersin, Sinan
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorGörür, Gözde
dc.contributor.authorMengüç, Meral Uluköylü
dc.date.accessioned2023-06-19T12:50:42Z
dc.date.available2023-06-19T12:50:42Z
dc.date.issued2021en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction Hodgkin lymphoma (HL) is unusual among malignancies, with inflammation playing such a prominent role in its pathogenesis. S100A8/A9 (calprotectin) is a heterodimeric protein, which has a role in the inflammatory response and oncogenesis. In this study in HL patients, the correlation between serum S100A8/A9 levels and treatment responses was investigated along with whether this marker is correlated with other inflammatory markers. Materials and Methods Thirty-three HL patients and 20 healthy volunteers were included. Demographic and clinical characteristics were recorded. Calprotectin levels were measured with Human S100A8/A9 Heterodimer Quantikine ELISA kit. Calprotectin levels were measured twice in patients, before and after treatment, and once in the control group. Treatment responses were evaluated with positron emission tomography-computed tomography (PET-CT). Results The mean age of patients was 44.3 +/- 18.1 (66.3% male). The median (IQR) values of S100A8/A9 before and after treatment in the patient group were 4.98 (2.6-7.8) and 1.87 (1.1-4.8)mu g/mL. Median (IQR) S100A8/A9 concentration in the control group was 1.41 (0.98-2.73)mu g/mL. In patients, pretreatment values were significantly higher than in controls (P < .001). However, median values of patients after treatment and controls were similar. Patient median S100A8/A9 levels were significantly lower post-treatment compared with pretreatment values (P = .001). When inflammatory markers were examined within groups, no relationship was found between markers. In ROC analysis, a S100A8/A9 cutoff value of >= 3.31 mu g/mL accurately discriminated end-of-treatment PET positivity (AUC = 0.78; 95% CI 0.58-0.98; accuracy = 76.2%). Conclusion S100A8/A9 may be a potential biomarker for treatment response in HL independent of inflammation. This is the first study to investigate and show this finding. However, further large-scale studies are still required.en_US
dc.identifier.citationŞumnu, Ş., Mehtap, Ö., Mersin, S., Toptaş, T., Görür, G., Gedük, A., ... & Hacıhanifioğlu, A. (2021). Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma. International journal of laboratory hematology, 43(4), 638-644.en_US
dc.identifier.doi10.1111/ijlh.13559
dc.identifier.endpage644en_US
dc.identifier.issn1751-5521
dc.identifier.issn1751-553X
dc.identifier.issue4en_US
dc.identifier.pmid33904653en_US
dc.identifier.scopus2-s2.0-85111607709en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage638en_US
dc.identifier.urihttp://dx.doi.org/10.1111/ijlh.13559
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11143
dc.identifier.volume43en_US
dc.identifier.wosWOS:000644426200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorMengüç, Meral Uluköylü
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofInternational Journal of Laboratory Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkeren_US
dc.subjectCalprotectinen_US
dc.subjectHodgkin Lymphomaen_US
dc.subjectA9en_US
dc.subjectSuppressor-Cellsen_US
dc.subjectExpressionen_US
dc.titleSerum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphomaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
seyma-sumnu.pdf
Boyut:
786.82 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu